Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s traded shares stood at 0.43 million during the last session, with the company’s beta value hitting 3.09. At the close of trading, the stock’s price was $5.75, to imply a decrease of -4.17% or -$0.25 in intraday trading. The CRBP share’s 52-week high remains $61.90, putting it -976.52% down since that peak but still an impressive -2.26% since price per share fell to its 52-week low of $5.88. The company has a valuation of $70.33M, with an average of 0.23 million shares in intraday trading volume over the past 10 days and average of 240.72K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Corbus Pharmaceuticals Holdings Inc (CRBP), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CRBP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.07.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) trade information
After registering a -4.17% downside in the last session, Corbus Pharmaceuticals Holdings Inc (CRBP) has traded red over the past five days. The 5-day price performance for the stock is -15.32%, and -30.56% over 30 days. With these gigs, the year-to-date price performance is -51.27%. Short interest in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) saw shorts transact 2.43 million shares and set a 8.52 days time to cover.
The extremes give us $35 and $60 for target low and target high price respectively. As such, CRBP has been trading -943.48% off suggested target high and -508.7% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 35.71% for the past 5-year period. While 2025 is set for a -35.82% return in earnings, projections for the next 5 years are at -15.65% annually.
CRBP Dividends
Corbus Pharmaceuticals Holdings Inc has its next earnings report out on 2025-Mar-10. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s Major holders
Corbus Pharmaceuticals Holdings Inc insiders hold 1.70% of total outstanding shares, with institutional holders owning 98.21% of the shares at 99.91% float percentage. In total, 98.21% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Corbus Pharmaceuticals Holdings Inc (CRBP) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 362.22 shares. This is just over 2.96% of the total shares, with a market valuation of $2.08 million. Data from the same date shows that the other fund manager holds a little less at 320.08, or 2.62% of the shares, all valued at about 1.84 million.
